Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

David L Wyles; Minhee Kang; Roy M Matining; Robert L Murphy; Marion G Peters; VHICS Study Team

doi:10.1093/ofid/ofy103

Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

Open Forum Infect Dis. 2018 Jun 4;5(6):ofy103. doi: 10.1093/ofid/ofy103. eCollection 2018 Jun.

Authors

David L Wyles¹, Minhee Kang², Roy M Matining², Robert L Murphy³, Marion G Peters⁴; VHICS Study Team

Affiliations

¹ Department of Medicine, Denver Health Medical Center, Denver, Colorado.
² Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
³ Department of Medicine, Northwestern University, Chicago, Illinois.
⁴ Department of Medicine, University of California San Francisco, San Francisco, California.

Abstract

Hepatitis C virus (HCV) recurrence rates were similar between those with HCV/HIV co-infection (0.35/100 person-years) and HCV infection (0.42/100 person-years). Low rates of recurrence likely represent enrollment of an HIV population at low risk for recurrence. Care should be taken not to label all HCV/HIV co-infected patients as being at high risk for HCV recurrence.

Keywords: HIV; direct acting antivirals; hepatitis C; recurrence.

Abstract

Grants and funding